Does the primary tumor site in stage I extranodal natural killer/T-cell lymphoma matter?

Cui, Juan-Juan; Cai, Jing; Zhu, Qi-Wei; Bei, Yuan-Qi; Yang, Bai-Xia; Ma, Xue-Jun

Cui, Juan-Juan; Cai, Jing; Zhu, Qi-Wei; Bei, Yuan-Qi; Yang, Bai-Xia; Ma, Xue-Jun.

Afiliação

Cui JJ; Department of Radiation Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China.
Cai J; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China.
Zhu QW; Department of Radiation Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China.
Bei YQ; Department of Radiation Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China.
Yang BX; Department of Radiation Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China.
Ma XJ; Department of Radiation Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China.

Neoplasma ; 69(3): 700-707, 2022 May.

Article em En | MEDLINE | ID: mdl-35188402

Assuntos

Linfoma Extranodal de Células T-NK; Intervalo Livre de Doença; Humanos; Células Matadoras Naturais; Linfoma Extranodal de Células T-NK/terapia; Estadiamento de Neoplasias; Prognóstico; Estudos Retrospectivos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Extranodal de Células T-NK Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Neoplasma Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google